Claims for Patent: 6,291,659

Summary for Patent: 6,291,659

Title:	Transcripts of the MHC class I HLA-G gene and their applications
Abstract:	Transcripts of the major histocompatibility complex (MHC) Class I HLA-G gene which are present in foetal trophoblasts and/or in adult circulating mono-nuclear cells, as well as their applications. Either the said transcripts comprise, in succession in the 5\' to 3\' direction: a fragment encoding the signal peptide (exon 1), a fragment encoding the .alpha.1 domain (exon 2), a fragment encoding the .alpha.2 domain (exon 3), a fragment encoding the transmembrane TM domain (exon 5), a fragment encoding the cytoplasmic domain (exon 6) and the 3\' untranslated fragment (exon 8), which sequence is designated HLA-G4, or the said transcripts comprise intron 4.
Inventor(s):	Carosella; Edgardo Delfino (Paris, FR), Moreau; Philippe (Viry-Chatillon, FR), Gluckman; Eliane (Paris, FR), Kirszenbaum; Marek (Orsay, FR)
Assignee:	Commissariat a l\'Energie Atomique (Paris, FR)
Application Number:	08/958,316
Patent Claims:	1. A cDNA sequence derived from an mRNA of the human MHC HLA-G gene, characterized in that it comprises, in succession in the 5' to 3' direction: a sequence encoding the signal peptide (exon 1), a sequence encoding the .alpha.1 domain (exon 2), a sequence encoding the .alpha.2 domain (exon 3), a sequence encoding the transmembrane TM domain (exon 5), a sequence encoding the cytoplasmic domain (exon 6), and the 3' untranslated sequence (exon 8), said cDNA not containing a sequence encoding the .alpha.3 domain. 2. A cDNA sequence derived from mRNA of the human MHC HLA-G gene characterized in that it comprises, in succession in the 5' to 3' direction: a sequence encoding the .alpha.2 domain (exon 3), a sequence encoding the transinembrane TM domain (exon 5), a sequence encoding the cytoplasmic domain (exon 6), and the 3' untranslated fragment (exon 8) , said cDNA not containing a sequence encoding the .alpha.3 domain. 3. Sequence according to claim 2, characterized in that it encodes a protein in which the .alpha.2 domain and the transmembrane sequence of HLA-G are directly linked, and consists of SEQ ID NO:1. 4. Transcription product of the human MHC HLA-G cDNA of claim 1, characterized in that it includes, proceeding from the 5' end: a sequence encoding the signal peptide (exon 1), a sequence encoding the .alpha.1 domain (exon 2), a sequence encoding the .alpha.2 domain (exon 3), a sequence encoding the transmembrane TM domain (exon 5), and a 0.43 kb sequence encoding the cytoplasmic domain (exon 6) of HLA-G. 5. Oligonucleotide, characterized in that it consists of SEQ ID NO:2. 6. Oligonucleotide, characterized in that it consists of SEQ ID NO:3. 7. Oligonucleotide, characterized in that it consists of SEQ ID NO:4. 8. Oligonucleotide, characterized in that it consists of SEQ ID NO:5. 9. Oligonucleotide, characterized in that it consists of SEQ ID NO:6. 10. Probe characterized in that it consists of SEQ ID NO:4. 11. Probe, characterized in that it consists of SEQ ID NO:6. 12. Pair of primers, characterized in that the pair consists of an oligonucleotide of the SEQ ID NO:2 and an oligonucleotide of the SEQ ID NO:5. 13. Pair of primers, characterized in that the pair consists of an oligonucleotide of the SEQ ID NO:3 which is paired with an oligonucletide of the SEQ ID NO:5. 14. A cDNA sequence, designated HLA-G5 and derived from an mRNA of the human MHC HLA-G gene of adult circulating mononuclear cells, comprising, in succession in the 5' to 3' direction: a sequence encoding the signal peptide (exon 1), a sequence encoding the .alpha.1 domain (exon 2), a sequence encoding the .alpha.2 domain (exon 3), a sequence encoding the .alpha.3 domain (exon 4), intron 4, a sequence encoding the transmenibrane TM domain (exon 5), a sequence encoding the cytoplasmic domain (exon 6), and the 3' untranslated sequence (exon 8), for the preparation of a drug for use as an immunomodulating agent. 15. A cDNA sequence, designated HLA-G6 and derived from an mRNA of the human MHC HLA-G gene of adult circulating mononuclear cells, comprising, in succession in the 5' to 3' direction: a sequence encoding the signal peptide (exon 1), a sequence encoding the .alpha.1 domain (exon 2), a sequence encoding the .alpha.3 domain (exon 4), intron 4, a sequence encoding the transmembrane TM domain (exon 5), a sequence encoding the cytoplasmic domain (exon 6), and the 3' untranslated sequence (exon 8), for the preparation of a drug for use as an immunomodulating agent. 16. A sequence according to claim 14, without exon 6 and/or without exon 8. 17. Method for obtaining immunomodulating soluble proteins, comprising preparing an expression vector construct comprising a cDNA as defined according to claim 15 and causing expression of said vector construct to form soluble proteins. 18. Procedure for selecting and enriching undifferentiated hematopoietic cells, characterized in that it comprises: (a) withdrawing a sample selected from the group consisting peripheral blood, umbilical cord blood and bone marrow, (b) bringing the sample into contact with anti-CD34 antibodies, (c) separating the cell complexes formed which contain a CD34 antigen-anti-CD34 antibody, (d) carrying out an in-situ RT PCR on the cells obtained in step (c) in the presence of sequence fragments of claim 1 as primers which are labeled with a fluorochrome, (e) separating the fluorescent cells which are obtained, and (f) selecting pluripotent, immature nonfluorescent cells and obtaining undifferentiated hematopoietic cells. 19. Procedure for detecting cells which express a transcript of the human MHC HLA-G gene comprising: (a) bringing blood cells into contact with a pair of primers that are sequence fragments of the cDNA of claim 1 which are labeled, and (b) performing an RT PCR using said primers, and (c) separating the labeled cells by any appropriate means and detecting cells which express a transcript of the human MHC HLA-G gene. 20. Procedure for detecting adult circulating mononuclear cells expressing a transcript with intron 4, characterized in that it comprises the in-situ implementation of an RT PCR, by: (a) bringing blood cells into contact with a pair of labeled primers which are sequence fragments according to claim 1, (b) selecting transcripts comprising intron 4, by hybridization with a probe having the sequence of SEQ ID NO:10 or 11; and (c) separating the labeled cells by any appropriate means and detecting adult circulating mononuclear cells. 21. Procedure for specifically separating circulating mononuclear cells, characterized in that it comprises the in-situ implementation of an RT PCR, by: (a) bringing blood cells into contact with a pair of primers that are sequence fragments of claim 1 which are labeled, and (b) separating the labeled cells in a suitable manner and separating mononuclear cells. 22. An isolated cDNA sequence derived from an mRNA of the human MHC HLA-G gene characterized in that it comprises, in succession in the 5' to 3' direction: a sequence encoding the signal peptide (exon 1), a sequence encoding the .alpha.1 domain (exon 2), a sequence encoding the .alpha.2 domain (exon 3), a sequence encoding the transmembrane TM domain (exon 5), a sequence encoding the cytoplasmic domain (exon 6), and the 3' untranslated sequence (exon 8), which sequence is designated HLA-G4 and is present in trophoblasts of the first trimester of gestation as well as in adult circulating mononuclear cells, said cDNA sequence not including a sequence encoding the .alpha.3 domain (exon 4).

Details for Patent 6,291,659

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2014-03-18
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2014-03-18
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2014-03-18